Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Cardiovascular Diabetology · 2024
DOI: 10.1186/s12933-024-02424-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Diabetology, 2024. Verfasst von Chung-An Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Databases, Factual, Diabetes Mellitus, Type 2, Renal Dialysis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have demonstrated associations with lowering cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, the impact of SGLT-2is on individuals at dialysis commencement remains unclear. The aim of this real-world study is to study the association between SGLT-2is and outcomes in patients with T2DM at dialysis commencement.
Methods
This is a retrospective cohort study of electronic health records (EHRs) of patients with T2DM from TriNetX Research Network database between January 1, 2012, and January 1, 2024. New-users using intention to treatment design was employed and propensity score matching was utilized to select the cohort. Clinical outcomes included major adverse cardiac events (MACE) and all-cause mortality. Safety outcomes using ICD-10 codes, ketoacidosis, urinary tract infection (UTI) or genital infection, dehydration, bone fracture, below-knee amputation, hypoglycemia, and achieving dialysis-free status at 90 days and 90-day readmission.
Results
Of 49,762 patients with T2DM who initiated dialysis for evaluation, a mere 1.57% of patients utilized SGLT-2is within 3 months after dialysis. 771 SGLT-2i users (age 63.3 ± 12.3 years, male 65.1%) were matched with 771 non-users (age 63.1 ± 12.9 years, male 65.8%). After a median follow-up of 2.0 (IQR 0.3–3.9) years, SGLT-2i users were associated with a lower risk of MACE (adjusted Hazard Ratio [aHR] = 0.52, p value < 0.001), all-cause mortality (aHR = 0.49, p < 0.001). SGLT-2i users were more likely to become dialysis-free 90 days after the index date (aHR = 0.49, p < 0.001). No significant differences were observed in the incidence of ketoacidosis, UTI or genital infection, hypoglycemia, dehydration, bone fractures, below-knee amputations, or 90-day readmissions.
Conclusions
Our findings indicated a lower incidence of all-cause mortality and MACE after long-term follow-up, along with a higher likelihood of achieving dialysis-free status at 90 days in SGLT-2i users. Importantly, they underscored the potential cardiovascular protection and safety of SGLT-2is use in T2DM patients at the onset of dialysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
- Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Healthy and Welfare, Taoyuan, Taiwan.
- Department of Biomedical Engineering, Chung Yuan Christian University, Chungli, Taiwan.
Zitieren
APA
Wang, C. A., Lin, L. C., Chen, J. Y., Wang, W. J., & Wu, V. C. (2024). Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-024-02424-7
Vancouver
Wang CA, Lin LC, Chen JY, Wang WJ, Wu VC. Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis. Cardiovascular Diabetology. 2024. doi:10.1186/s12933-024-02424-7
BibTeX
@article{Wang2024,
author = {Wang, Chung-An and Lin, Li-Chun and Chen, Jui-Yi and Wang, Wei-Jie and Wu, Vin-Cent},
title = {Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis},
journal = {Cardiovascular Diabetology},
year = {2024},
doi = {10.1186/s12933-024-02424-7}
}
EUVIMED